DanCann Pharma A/S has successfully completed pre-validation batches and expects final approval from the Danish Medicines Agency by the end of summer
COPENHAGEN, Denmark, 26 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, is pleased to announce the completion of its pre-validation batches. These batches are paving the way for the Company's forthcoming application to the Danish Medicines Agency for its final inspection of Biotech Pharm1 (“BP1”), seeking approval for the release of its products. This achievement aligns closely with the Company's original expectations, with minor adjustments made along the way.As communicated in December 2022, three